CRO/Sponsor

Continual change is coming as sponsors' sourcing requirements diverge from the major CROs.

Where do CRO's turn next? What does pharma do about it?

Cancer trial recruitment is struggling-adult participation is limited.

Optimizing early phase trials key to the success of novel cytotoxics and targeted therapies.

Are emerging markets the only answer to oncology clinical trial recruitment?

Where do CRO's turn next? What does pharma do about it?

Continual change is coming as sponsors' sourcing requirements diverge from the major CROs.

Researchers who work on HIV vaccines face a major challenge: convincing members of at-risk communities to volunteer for these trials.

Partnering with CROs and using a blinded independent central review can increase trial success.

Guatemala is multi-ethnic, multilingual, and multi-cultural-ideal for international trials.

Research shows four factors best predict successful patient enrollment in clinical trials.

BRIC governements are working to make it easier to conduct trials in country.

Drug, biological supply, and medical device manufacturers must track all payments of over $10.

Knowledge is power, but power is of no value if you don't exercise it.

A simple but overlooked way to save millions of dollars during new drug development.

Two unique techniques help characterize pharmacodynamic drug effects in healthy subjects.

Collaborative communities may hold the key to transforming a half-century's old R&D paradigm.

The proper storage of research documents remains an essential aspect of the clinical trials process.

Transfer of material between the supply cahins can be time consuming and complicated

With more clinical trials conducted overseas, sponsors are facing new obstacles.

Creating a drug's safety profile through the use of benefit-risk assessments during development.

Medicine is not quantum mechanics where we cannot predict when an event will occur

Conducting clinical research in the East brings a new group of challenges to sponsors

Improvements in image acquisition and read quality: A look at the value of standardization in oncology trials.

Better access to information vastly improves the decision-making process.

Noncompliance with the US Foreign Corrupt Practices Act carries heavy penalties.

The importance of openness and loyalty cannot be overlooked when cultivating a parternship.

The partnership is an example of how CROs and sponsors interact in the ever-evolving clinical trial industry.

Lessons learned from the recruitment of colorectal cander patients into clinical trials.

Greater product value and innovation accomplished with sponsor-service relationships.